GlassScriptPhysician profile
Alan C Dejarnatt
NPI 1598750184
$7,146.45
in general payments reported to CMS, 2019-2025
26 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $313 · 2021: $910 · 2022: $1,024 · 2023: $916 · 2024: $941 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,809 · Education: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,809.32 |
| Education | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,744.29 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $914.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $626.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $527.79 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $497.39 | 2019-2025 | |
| Genentech USA, INC. | $478.56 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $470.10 | 2019-2025 | |
| Amgen INC. | $240.06 | 2022-2025 | Tezspire |
| Kaleo, INC. | $239.90 | 2019-2023 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $198.91 | 2025 | Neffy |
| Octapharma USA, INC. | $176.94 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $149.09 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $130.25 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.68 | 2021-2025 | Cuvitru, Takhzyro |
| Grifols USA, LLC | $114.11 | 2021-2025 | Xembify |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $108.55 | 2019 | |
| Alk-Abello, INC | $81.95 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $60.30 | 2025 | Dawnzera |
| Incyte Corporation | $58.17 | 2025 | Opzelura |
| Optinose US, INC. | $54.65 | 2021-2024 | |
| Cycle Pharmaceuticals INC | $44.14 | 2025 | Sajazir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.52 | 2019-2022 | |
| Leo Pharma INC. | $21.91 | 2023 | Adbry |
| Boston Scientific Corporation | $18.99 | 2024 | |
| Paratek Pharmaceuticals, INC. | $18.46 | 2025 | Xhance |
| Lilly USA, LLC | $13.66 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Dejarnatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.